ECSP20026436A - Métodos de uso y composiciones que contienen dulaglutida - Google Patents

Métodos de uso y composiciones que contienen dulaglutida

Info

Publication number
ECSP20026436A
ECSP20026436A ECSENADI202026436A ECDI202026436A ECSP20026436A EC SP20026436 A ECSP20026436 A EC SP20026436A EC SENADI202026436 A ECSENADI202026436 A EC SENADI202026436A EC DI202026436 A ECDI202026436 A EC DI202026436A EC SP20026436 A ECSP20026436 A EC SP20026436A
Authority
EC
Ecuador
Prior art keywords
methods
compositions containing
dulaglutida
dulaglutide
doses
Prior art date
Application number
ECSENADI202026436A
Other languages
English (en)
Spanish (es)
Inventor
Lai San Tham
Zvonko Milicevic
David Andrew Cox
David Bradley Woodward
Andrew Gordon Werner
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64572530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP20026436(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP20026436A publication Critical patent/ECSP20026436A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
ECSENADI202026436A 2017-11-21 2020-05-20 Métodos de uso y composiciones que contienen dulaglutida ECSP20026436A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762589244P 2017-11-21 2017-11-21

Publications (1)

Publication Number Publication Date
ECSP20026436A true ECSP20026436A (es) 2020-06-30

Family

ID=64572530

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202026436A ECSP20026436A (es) 2017-11-21 2020-05-20 Métodos de uso y composiciones que contienen dulaglutida

Country Status (22)

Country Link
US (2) US11576950B2 (enExample)
EP (1) EP3713593A2 (enExample)
JP (3) JP7221956B2 (enExample)
KR (2) KR20220146656A (enExample)
CN (2) CN120478602A (enExample)
AU (2) AU2018372709B2 (enExample)
BR (1) BR112020007817A2 (enExample)
CA (1) CA3082625A1 (enExample)
CL (1) CL2020001252A1 (enExample)
CR (1) CR20200202A (enExample)
DO (1) DOP2020000104A (enExample)
EA (1) EA202090971A1 (enExample)
EC (1) ECSP20026436A (enExample)
IL (1) IL274563B2 (enExample)
JO (1) JOP20200126A1 (enExample)
MA (1) MA50798A (enExample)
MX (1) MX2020005231A (enExample)
PE (1) PE20200847A1 (enExample)
PH (1) PH12020550795A1 (enExample)
SG (1) SG11202003687RA (enExample)
UA (1) UA127588C2 (enExample)
WO (1) WO2019103875A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7728176B2 (ja) * 2019-03-15 2025-08-22 イーライ リリー アンド カンパニー 保存製剤
MX2022009383A (es) * 2020-01-30 2022-11-07 Lilly Co Eli Usos terapéuticos de dulaglutida.
EP4153130A1 (en) * 2020-05-19 2023-03-29 F. Hoffmann-La Roche AG The use of chelators for the prevention of visible particle formation in parenteral protein solutions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1355942T3 (da) 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
CA2528591C (en) 2003-06-12 2013-01-08 Eli Lilly And Company Glp-1 analog fusion proteins
EA011166B1 (ru) 2004-12-22 2009-02-27 Эли Лилли Энд Компани Композиции слитых белков-аналогов glp-1
EA201070121A1 (ru) 2007-07-10 2010-06-30 Эли Лилли Энд Компани Лекарственная форма, содержащая слитый белок glp-1-fc
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
WO2016168388A2 (en) * 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
JP7191043B2 (ja) 2017-06-01 2022-12-16 イーライ リリー アンド カンパニー 慢性腎疾患の治療のためのデュラグルチド

Also Published As

Publication number Publication date
UA127588C2 (uk) 2023-10-25
IL274563B2 (en) 2023-12-01
AU2022203372B2 (en) 2025-04-10
AU2018372709B2 (en) 2022-04-28
US11576950B2 (en) 2023-02-14
US20200330558A1 (en) 2020-10-22
KR20200076705A (ko) 2020-06-29
SG11202003687RA (en) 2020-06-29
CR20200202A (es) 2020-08-20
AU2022203372A1 (en) 2022-06-09
BR112020007817A2 (pt) 2020-10-06
EP3713593A2 (en) 2020-09-30
CN120478602A (zh) 2025-08-15
CN111356472A (zh) 2020-06-30
PH12020550795A1 (en) 2021-04-19
IL274563A (en) 2020-06-30
JOP20200126A1 (ar) 2020-05-21
WO2019103875A3 (en) 2019-07-25
NZ763815A (en) 2023-11-24
JP7221956B2 (ja) 2023-02-14
JP2024056908A (ja) 2024-04-23
WO2019103875A2 (en) 2019-05-31
KR102589234B1 (ko) 2023-10-16
CA3082625A1 (en) 2019-05-31
AU2018372709A1 (en) 2020-05-14
EA202090971A1 (ru) 2020-08-07
IL274563B1 (en) 2023-08-01
JP2021502379A (ja) 2021-01-28
US20240189394A1 (en) 2024-06-13
KR20220146656A (ko) 2022-11-01
MX2020005231A (es) 2020-08-24
CL2020001252A1 (es) 2020-10-30
JP2022062153A (ja) 2022-04-19
MA50798A (fr) 2020-09-30
DOP2020000104A (es) 2020-08-31
PE20200847A1 (es) 2020-08-18

Similar Documents

Publication Publication Date Title
MX2020005063A (es) Inhibidores de kras g12c.
CL2018002874A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
DOP2017000298A (es) Reguladores de nrf2
CR20160419A (es) Nuevos compuestos biciclicos
MX388018B (es) Anticuerpos anti-pd1 y métodos de uso.
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
SV2017005471A (es) Derivados de quinazolina utilizados para tratar el vih
CR20150436A (es) Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
BR112021011124A2 (pt) Anelossomos e métodos de uso
MX378386B (es) Composiciones antiirritantes sinérgicas de taurina y aloe.
MX2020001885A (es) Formulaciones de daptomicina.
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
UY36898A (es) Variantes de hppd y métodos de uso
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio
CO2019015102A2 (es) Nuevos derivados de xantina sustituidos
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
ECSP20026436A (es) Métodos de uso y composiciones que contienen dulaglutida
MX2016000219A (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos.
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo